References

Global burden of 87 risk factors in 204 countries and territories, 1990-2019: a systematic analysis for the Global burden of disease study 2019

10.1016/s0140-6736(20)30752-2 · 2020 · External reference

Trends in blood pressure control among US adults with hypertension, 1999-2000 to 2017-2018

10.1001/jama.2020.14545 · 2020 · External reference

Reprint of: prevention and control of hypertension

10.1016/j.jacc.2018.10.022 · 2018 · External reference

Unresolved reference

External reference

Obesity-induced hypertension

10.1161/circresaha.116.305697 · 2015 · External reference

Obesity, kidney dysfunction and hypertension: mechanistic links

10.1038/s41581-019-0145-4 · 2019 · External reference

From pathophysiology to novel approaches for obesity-associated hypertension

10.1093/ckj/sfaf218 · 2025 · External reference

2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the prevention, detection, evaluation, and management of high blood pressure in adults

10.1016/j.jacc.2025.05.007 · 2025 · External reference

10.1093/eurheartj/ehae178

10.1093/eurheartj/ehae178 · 2024 · External reference

Unresolved reference

External reference

Weight-loss strategies for prevention and treatment of hypertension: a scientific statement from the American heart association

10.1161/hyp.0000000000000202 · 2021 · External reference

Effects of the DASH diet alone and in combination with exercise and weight loss on blood pressure and cardiovascular biomarkers in men and women with high blood pressure: the ENCORE Study

10.1001/archinternmed.2009.470 · 2010 · External reference

Sodium reduction and weight loss in the treatment of hypertension in older PersonsA randomized controlled trial of nonpharmacologic interventions in the elderly (TONE)

10.1001/jama.279.11.839 · 1998 · External reference

Effects of bariatric surgery versus medical therapy on the 24-hour ambulatory blood pressure and the prevalence of resistant hypertension

10.1161/hypertensionaha.118.12290 · 2019 · External reference

Efficacy of GLP-1 receptor agonists on weight loss, BMI, and waist circumference for patients with obesity or overweight: a systematic review, meta-analysis, and meta-regression of 47 randomized Controlled trials

10.2337/dc24-1678 · 2025 · External reference

10.1161/hypertensionaha.122.19248

10.1161/hypertensionaha.122.19248 · 2025 · External reference

Tirzepatide and blood pressure reduction: stratified analyses of the SURMOUNT-1 randomised controlled trial

10.1136/heartjnl-2024-324170 · 2024 · External reference

Systolic blood pressure reduction with tirzepatide in patients with type 2 diabetes: insights from SURPASS clinical program

10.1186/s12933-023-01797-5 · 2023 · External reference

Cardiometabolic parameter change by weight regain on tirzepatide withdrawal in adults with obesity: a post hoc analysis of the SURMOUNT-4 trial

10.1001/jamainternmed.2025.6112 · 2026 · External reference

Obstructive sleep apnea and cardiometabolic disease: obesity, hypertension, and diabetes

10.1161/circresaha.125.325676 · 2025 · External reference

Tirzepatide for the treatment of obstructive sleep apnea and obesity

10.1056/nejmoa2404881 · 2024 · External reference

The blood pressure-lowering property of subcutaneous semaglutide: a systematic review, meta-analysis, and meta-regression

10.1007/s40618-024-02459-3 · 2025 · External reference

Meta-analysis of the effect of semaglutide on blood pressure in Obese populations

10.1007/s40256-025-00738-9 · 2025 · External reference

Abstract 4141117: semaglutide and cardiovascular outcomes by blood pressure in the SELECT trial

10.1161/circ.150.suppl_1.4141117 · 2024 · External reference

The effect of semaglutide on blood pressure in patients with type-2 diabetes: a systematic review and meta-analysis

10.1007/s12020-023-03636-9 · 2024 · External reference

Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase 3, double-blind, randomised, multicentre, placebo-controlled trial

10.1016/s0140-6736(25)02165-8 · 2025 · External reference

Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b ATTAIN-MAINTAIN trial

10.1038/s41591-026-04386-7 · 2026 · External reference

Daily oral GLP-1 receptor agonist Orforglipron for adults with obesity

10.1056/nejmoa2302392 · 2023 · External reference

Orforglipron, an oral small-molecule GLP-1 receptor agonist, in early type 2 diabetes

10.1056/nejmoa2505669 · 2025 · External reference

Oral semaglutide at a dose of 25 mg in adults with overweight or obesity

10.1056/nejmoa2500969 · 2025 · External reference

Unresolved reference

External reference

Pharmacokinetic bioequivalence of Orforglipron tablets and capsules in healthy participants with obesity or overweight

10.1111/dom.70783 · 2026 · External reference

Efficacy and safety of oral orforglipron in patients with type 2 diabetes: a multicentre, randomised, dose-response, phase 2 study

10.1016/s0140-6736(23)01302-8 · 2023 · External reference

Toward better practice of covariate adjustment in analyzing randomized clinical trials

10.1080/01621459.2022.2049278 · 2023 · External reference

Identifying and treating resistant hypertension in PRECISION: a randomized long-term clinical trial with aprocitentan

10.1111/jch.14517 · 2022 · External reference

Orforglipron, an oral small-molecule GLP-1 receptor agonist for obesity treatment

10.1056/nejmoa2511774 · 2025 · External reference

Tirzepatide once weekly for the treatment of obesity

10.1056/nejmoa2206038 · 2022 · External reference

Lorundrostat efficacy and safety in patients with uncontrolled hypertension

10.1056/nejmoa2501440 · 2025 · External reference

Efficacy and safety of Baxdrostat in uncontrolled and resistant hypertension

10.1056/nejmoa2507109 · 2025 · External reference

RNA interference with Zilebesiran for mild to moderate hypertension: the KARDIA-1 randomized clinical trial

10.1001/jama.2024.0728 · 2024 · External reference

Unresolved reference

2000 · External reference